What’s on CS111: The final covers programming basics, data structures, algorithms, recursion, and problem-solving, often through multiple-choice and coding questions. How to prepare: Review lectures ...

Penn researchers have developed a smarter AI method for solving notoriously difficult inverse equations, which help ...

ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.

Penn Engineers have developed a new way to use AI to solve inverse partial differential equations (PDEs), a particularly ...

We’re being sold a world where there’s no room for reflection or spontaneity. This is the Black Mirror stage of capitalism, says Alexander Hurst, who writes for Guardian Europe from Paris ...

All right. Good morning, again, for I see some familiar face in the last one, but thanks for sticking around. It's good to see everybody, and welcome back to TD Cowen's 46th Annual Healthcare ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...